Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Immunome (IMNM) Return on Capital Employed (2023 - 2025)

Immunome (IMNM) has disclosed Return on Capital Employed for 3 consecutive years, with 0.5% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Capital Employed rose 107.0% year-over-year to 0.5%, compared with a TTM value of 0.5% through Dec 2025, up 107.0%, and an annual FY2025 reading of 0.54%, up 165.0% over the prior year.
  • Return on Capital Employed was 0.5% for Q4 2025 at Immunome, up from 0.88% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.5% in Q4 2025 and bottomed at 1.57% in Q4 2024.
  • Average Return on Capital Employed over 3 years is 1.02%, with a median of 1.01% recorded in 2024.
  • The sharpest move saw Return on Capital Employed plummeted -47bps in 2024, then skyrocketed 107bps in 2025.
  • Year by year, Return on Capital Employed stood at 1.11% in 2023, then tumbled by -42bps to 1.57% in 2024, then surged by 68bps to 0.5% in 2025.
  • Business Quant data shows Return on Capital Employed for IMNM at 0.5% in Q4 2025, 0.88% in Q3 2025, and 0.76% in Q2 2025.